Commercial-stage biotech companies
20 listed drug developers whose lead program is marketed, largest first, with the next catalyst each has disclosed.
| Company | Ticker | Lead program | Indication | Next catalyst |
|---|---|---|---|---|
| ELI LILLY & Co | LLY | Foundayo (orforglipron) | Obesity | — |
| Johnson & Johnson | JNJ | — | — | — |
| Amgen Inc | AMGN | Repatha (evolocumab) | Hypercholesterolemia / cardiovascular risk reduction | — |
| Halozyme Therapeutics, Inc. | HALO | Hylenex (rHuPH20) | Subcutaneous drug dispersion / hydration | — |
| Jazz Pharmaceuticals plc | JAZZ | Ziihera (zanidatamab) sBLA | HER2+ cancer | — |
| Indivior Pharmaceuticals, Inc. | INDV | SUBLOCADE (buprenorphine extended-release monthly injection) | Opioid use disorder | — |
| Alvotech | ALVO | SIMLANDI (adalimumab-ryvk) | Humira (adalimumab) biosimilar; autoimmune disease | — |
| Nuvation Bio Inc. | NUVB | Taletrectinib (IBTROZI) | ROS1-positive non-small cell lung cancer | date not stated — Initiate pivotal Phase 3 (grade 2 IDH1-mutant glioma, ex-US) and Phase 2 (post-vorasidenib, US) |
| Innoviva, Inc. | INVA | Giapreza / Xacduro / Xerava / Zevtera / Nuzolvence (marketed anti-infective and critical-care portfolio) | Serious infections; vasodilatory shock | — |
| Harrow, Inc. | HROW | VEVYE (cyclosporine ophthalmic solution) 0.1% and branded ophthalmic portfolio | dry eye disease (VEVYE); portfolio spans ocular anesthesia, retina, post-operative inflammation and others | 2027 — Commercial launch (FDA-approved EYLEA biosimilar) |
| Collegium Pharmaceutical, Inc | COLL | Commercial portfolio (Jornay PM, Azstarys, Belbuca, Xtampza ER, Nucynta, Symproic) | ADHD and moderate to severe pain | — |
| AngioDynamics, Inc. | ANGO | — | — | — |
| Evolus, Inc. | EOLS | Jeuveau (prabotulinumtoxinA-xvfs) | temporary improvement in appearance of moderate to severe glabellar lines (aesthetic) | H2 2026 — FDA PMA approval |
| Emergent BioSolutions Inc. | EBS | Marketed MCM and naloxone portfolio (BioThrax, CYFENDUS, ACAM2000, ANTHRASIL, raxibacumab, CNJ-016, NARCAN, KLOXXADO) | Anthrax, smallpox/mpox, opioid overdose, other public health threats | — |
| Amarin Corp Plc\uk | AMRN | VASCEPA (icosapent ethyl) | Severe hypertriglyceridemia (MARINE) and reduction of persistent cardiovascular risk in statin-treated high-risk patients (REDUCE-IT) | — |
| Journey Medical Corp | DERM | Emrosi (minocycline modified-release capsules 40 mg) | Inflammatory lesions of rosacea in adults | — |
| Outlook Therapeutics, Inc. | OTLK | LYTENAVA (bevacizumab-vikg) | wet age-related macular degeneration | Q4 2026 — US commercial launch |
| LENZ Therapeutics, Inc. | LENZ | VIZZ (aceclidine ophthalmic solution) 1.44% (LNZ100) | presbyopia | — |
| Citius Oncology, Inc. | CTOR | LYMPHIR (denileukin diftitox-cdxl) | persistent or recurrent cutaneous T-cell lymphoma | — |
| Aytu Biopharma, Inc | AYTU | EXXUA (gepirone) extended-release | major depressive disorder in adults | — |
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.